Total trials
3,442
Active
488
Phase 3
790
Total enrollment
315,391,465
Pipeline matrix
Showing 40 of 417 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Trastuzumab deruxtecan | — | 25 | |||||
| Olaparib | — | 46 | |||||
| Datopotamab deruxtecan | — | — | 13 | ||||
| Anifrolumab | — | 23 | |||||
| Acalabrutinib | — | 18 | |||||
| Benralizumab | — | 37 | |||||
| abiraterone acetate | — | — | 8 | ||||
| Enzalutamide | — | — | 7 | ||||
| Dapagliflozin | — | 91 | |||||
| Prednisone | — | — | — | — | 2 | ||
| Budesonide/Glycopyrronium/Formoterol Fumarate | — | — | — | — | — | 1 | |
| Albuterol and budesonide inhalation aerosol | — | — | — | — | — | 1 | |
| Dexamethasone mouthwash | — | — | — | — | — | 1 | |
| Osimertinib+cisplatin or carboplatin + pemetrexed Edit | — | — | — | — | — | 1 | |
| Breztri Aerosphere | — | — | — | — | — | 1 | |
| Durvalumab | — | 85 | |||||
| Carboplatin | — | — | — | 54 | |||
| Cisplatin | — | — | — | 46 | |||
| Paclitaxel | — | — | — | 46 | |||
| Rilvegostomig | — | — | — | 22 | |||
| Pemetrexed | — | — | — | 24 | |||
| Pembrolizumab | — | — | — | — | 16 | ||
| Volrustomig | — | — | — | 15 | |||
| Tremelimumab | — | — | 26 | ||||
| Osimertinib | — | 21 | |||||
| Capecitabine | — | — | — | 16 | |||
| Bevacizumab | — | — | — | 15 | |||
| Gemcitabine | — | — | — | 23 | |||
| Capivasertib | — | — | — | 18 | |||
| Dato-DXd | — | — | — | — | 10 | ||
| Tezepelumab | — | 22 | |||||
| Saruparib | — | — | — | 9 | |||
| Fulvestrant | — | 32 | |||||
| Docetaxel | — | — | 19 | ||||
| 5-Fluorouracil | — | — | — | 11 | |||
| Nab-paclitaxel | — | — | — | 8 | |||
| AZD0780 | — | — | — | 16 | |||
| Savolitinib | — | — | — | 13 | |||
| Camizestrant | — | — | — | 9 | |||
| Oleclumab | — | — | — | 8 |
377 more active programs hidden
Next readouts
- 2008-06-17
- 2009-02-06
- 2009-02-27
- 2009-07-30
- 2011-10-10
- 2016-06-07
- 2016-09-19
- 2018-05-17
- 2018-10-04
- 2019-08-18
Top conditions
- Asthma251
- Healthy151
- Type 2 Diabetes Mellitus122
- Breast Cancer113
- Chronic Obstructive Pulmonary Disease95
- Type 2 Diabetes95
- Schizophrenia71
- Healthy Volunteers62
Frequently asked questions about AstraZeneca
- How many clinical trials does AstraZeneca have on ClinicalTrials.gov?
- AstraZeneca is listed as the lead sponsor on 3,442 clinical trials in ClinicalTrials.gov, 488 of which are currently active (recruiting, enrolling, or ongoing).
- How many of AstraZeneca's trials are in Phase 3?
- 790 of AstraZeneca's trials are in Phase 3, spread across 417 active drug programs.
- What therapeutic areas does AstraZeneca focus on?
- AstraZeneca's most-studied conditions on ClinicalTrials.gov are Asthma, Healthy, Type 2 Diabetes Mellitus, Breast Cancer, Chronic Obstructive Pulmonary Disease.
- When are AstraZeneca's next clinical trial readouts?
- AstraZeneca has 10 upcoming primary-completion readouts tracked here; the soonest is “AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies”, expected around 2008-06-17.